Efficacy of the Targeted Triple Therapy With Giltertinib, Venetoclax, and Azacitidine as a Bridge to Allogenic Hematopoietic Stem Cell Transplant in Relapsed Refractory FLT3‐Positive Acute Myeloid Leukemia in Children